HALOZYME THERAPEUTICS, INC. |
Director |
Common Stock |
15.8K |
$606K |
$38.49 |
Apr 25, 2024 |
Direct |
Atea Pharmaceuticals, Inc. |
Director |
Common Stock |
33.2K |
$133K |
$4.00 |
Jun 16, 2024 |
Direct |
HALOZYME THERAPEUTICS, INC. |
Director |
Option to Purchase Common Stock |
8.8K |
$122K |
$13.87 |
Apr 25, 2024 |
Direct |
Atea Pharmaceuticals, Inc. |
Director |
Restricted Stock Units |
29.6K |
$103K |
$3.49 |
Jun 21, 2024 |
Direct |
Adaptimmune Therapeutics PLC |
Director |
Option to purchase Ordinary Shares |
500K |
|
|
Jul 1, 2022 |
Direct |
Ovid Therapeutics Inc. |
Director |
Stock Option (Right to Buy) |
90K |
|
|
Dec 12, 2024 |
Direct |
Atea Pharmaceuticals, Inc. |
Director |
Stock Option (Right to Buy) |
41.2K |
|
|
Jun 21, 2024 |
Direct |
Fusion Pharmaceuticals Inc. |
Director |
Stock Opion (Right to Buy) |
17K |
|
|
Jun 14, 2023 |
Direct |
Fusion Pharmaceuticals Inc. |
Director |
Stock Option (Right to Buy) |
0 |
|
|
Jun 4, 2024 |
Direct |
Jounce Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
0 |
|
|
May 3, 2023 |
Direct |